Johnson & Johnson, Sanofi, and Others Announce Major Strategic and Organizational Restructuring

　　【Pharmaceutical Network Industry Dynamics】Focusing on innovation and core businesses while divesting non-core operations has consistently been a strategic transformation route chosen by numerous pharmaceutical enterprises. It is reported that since 2023, business integration, mergers, and acquisitions among pharmaceutical companies both in and outside of China have remained highly active.
 

On September 14, Johnson & Johnson announced a brand update, integrating its two major businesses—medical technology and pharmaceuticals—under the Johnson & Johnson name. The pharmaceutical division, Janssen, will be renamed Johnson & Johnson Innovative Medicine, while the medical technology division will remain unchanged. According to reports, this brand renewal by Johnson & Johnson is mainly reflected in updates to the brand logo, color palette, connecting symbols, and artistic design. The new brand builds on the company's heritage while emphasizing a modern feel for key elements, showcasing its healthcare innovations in an inclusive manner, and bringing the company's essence of warmth and care to life.
 

Notably, on September 5, just before this, Xi'an Janssen held an employee meeting to officially announce the new president for the China region: Cherry Huang, Regional Managing Director of North Asia at Janssen Pharmaceuticals and CEO of Korea, will become the new president of Xi'an Janssen. The former president of Xi'an Janssen China, Zheng Lei, has left Johnson & Johnson to pursue external development opportunities.
 

According to industry insiders, apart from the change in the position of president, the entire leadership team of Janssen China has undergone a major reshuffle: Connie Cao has been appointed as the head of the Human Resources Department, FanYue Pan will serve as the head of the Immunotherapy Business Department, XuZheng He will lead the Neurology, Infectious Diseases, and Pulmonary Hypertension business, and Jian Chen, in addition to his current role as the head of the Oncology Business Department, will take on additional responsibilities for Market Access and Government Affairs.
 

On September 1, Sanofi China announced on its official WeChat account the update of its China strategy and organizational structure, establishing three new global management positions, including the Head of China R&D. Shi Wang, the first local CEO in Sanofi's 40-year history in China, has been promoted and appointed as the President of Sanofi Greater China. He will collaborate with key functional departments to comprehensively lead Sanofi China’s overall business, which includes three divisions: Specialty Care, Vaccines, and General Medicines.
 

Moreover, on August 15, AstraZeneca officially split its Respiratory, Gastrointestinal, and Autoimmunity Business Unit into two separate business units, appointing two heads. At the same time, it adjusted the team structure in Hong Kong and Macao, China. Stefan Chen (Chen Xi), former General Manager of Johnson & Johnson Medical (China) Ltd.'s Cardiovascular & Professional Solutions Business Unit, officially joined as Vice President of AstraZeneca China, leading the Respiratory Nebulization, Gastrointestinal, Vaccines and Immunotherapy, and Autoimmunity Business Units. Lin Xiao was appointed as Vice President of AstraZeneca China, overseeing the Respiratory Inhalation and Biologics Business Units, as well as operations in Hong Kong and Macao.
 

　　……
 

It is reported that, in order to enhance the competitiveness and future performance of the company, numerous enterprises both in China and abroad are accelerating the pace of business integration and strategic adjustment. Among them, the efficiency and quality of mergers and acquisitions as well as reorganization among listed companies in China have also been continuously improving this year.
 

For example, in March, Yiheda Industry planned to subscribe for a RMB 100 million contribution as a limited partner in Suzhou Fengyu Fusheng Equity Investment Partnership (Limited Partnership), where Beijing Fengyu Private Fund Management Co., Ltd., an affiliate acting as the general partner, serves as the executing partner. The company stated that this external investment will help accelerate the company's industrial integration efforts and further achieve its continuous, healthy, and stable development. It is expected to positively impact the company’s future financial condition, operating results, and business layout.
 

Conba disclosed in the investor relations activity record that its current and future strategic direction is the large-scale traditional Chinese medicine (TCM) health industry. The company will focus on this field for integration and layout. In terms of industrial integration, the company plans to complete the merger and restructuring of one or two pharmaceutical listed companies or time-honored TCM enterprises during the "14th Five-Year Plan" period. Regarding product integration, the company stated it will concentrate on the large brand and large variety project, continuously introducing potential blockbuster products with distinctive features suitable for various stages of development needs—similar to the total flavonoids of Hibiscus mutabilis oral patch—through purchases or the Marketing Authorization Holder (MAH) system, thereby constantly enriching the company’s product portfolio.
 

Overall, under the influence of continuously intensifying market competition and a changing environment for innovative drugs, pharmaceutical companies have made it a norm in their development process to adjust R&D strategies and business plans, as well as integrate resources. In the future, domestic companies will actively expand through multiple channels such as independent R&D, external introduction, investment, and mergers and acquisitions. While continuously building sustainable product pipelines, they will further enhance the core competitiveness of the company.
 

Disclaimer: In no event shall the information or opinions expressed in this article constitute investment advice to any person.